Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
United Kingdom
Biotech
AZ restarts £300M UK investment, but Merck not budging
AstraZeneca will resume a £300 million investment program in the U.K., seven months after freezing plans in frustration at drug pricing negotiations.
James Waldron
Apr 29, 2026 10:01am
US, UK regulators bolster medical device collaboration
Apr 6, 2026 10:20am
Fierce Pharma
UK government agrees to pharma deal, ensuring tariff reprieve
Apr 2, 2026 3:34pm
CRO Sygnature Discovery plans to send 60 UK staffers packing
Jan 30, 2026 5:00pm
AstraZeneca: Building a transparent pipeline from the ground up
Oct 10, 2025 9:52am
Oxford BioDynamics unveils new target use for EpiSwitch test
Oct 8, 2025 2:34pm
